TMTC4

Across TCGA pan-cancer cohorts, TMTC4 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMTC4 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMTC4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMTC4 expression acts as an unfavorable survival marker.

PDAC and LUAD are the cancer types where TMTC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.202	0.460	.001	28	view →
LUAD	OS	Quartile	II,III,IV	0.390	0.764	.007	21	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TMTC4–PDAC (DFS)

Open the PDAC breakdown →